Gara Jalqabaatti › Leukemia Myeloidii Hamaa › Washington › Seattle
Qorannoo klinikaalii Leukemia Myeloidii Hamaa Seattle, WA keessatti
Qorannoo 41 Leukemia Myeloidii Hamaa f Seattle fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- University of Washington Medical Center - Montlake, Seattle
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
Namoota walitti qabaa jiraSadarkaa 1
- Seattle Children's Hospital, Seattle
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- fi 1 dabalataa
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- Fred Hutchinson Cancer Center, Seattle
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Swedish Medical Center-First Hill, Seattle
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Namoota walitti qabaa jiraSadarkaa 3
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Swedish Medical Center-First Hill, Seattle
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Swedish Medical Center-First Hill, Seattle
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- University of Washington Medical Center - Montlake, Seattle
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Namoota walitti qabaa jiraSadarkaa 3
- Seattle Children's Hospital, Seattle
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Namoota walitti qabaa jiraSadarkaa 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Namoota walitti qabaa jiraSadarkaa 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia
Namoota walitti qabaa jiraSadarkaa 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms
Namoota walitti qabaa jira
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Home-Based Exercise Intervention (CAREFit-BMT) in Improving Heart Function Among Patients With High Risk Acute Myeloid Leukemia Undergoing Stem Cell Transplant
Namoota walitti qabaa jira
- Fred Hutch/University of Washington Cancer Consortium, Seattle
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
Namoota walitti qabaa jiraSadarkaa 1
- Fred Hutchinson Cancer Center, Seattle
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Namoota walitti qabaa jiraSadarkaa 1/2
- Seattle Children's Hospital, Seattle
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Namoota walitti qabaa jiraSadarkaa 3
- Seattle Children's Hospital, Seattle
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Namoota walitti qabaa jiraSadarkaa 1
- University of Washington, Seattle
Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
Namoota walitti qabaa jira
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Namoota walitti qabaa jiraSadarkaa 2
- Fred Hutchinson Cancer Center/University of Washington Cancer Consortium, Seattle
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
Namoota walitti qabaa jiraSadarkaa 2
- Fred Hutchinson Cancer Center, Seattle
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Namoota walitti qabaa jiraSadarkaa 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Namoota walitti qabaa jiraQorannoo ilaalaa
- Fred Hutchinson Cancer Research Center, Seattle
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Namoota walitti qabaa jiraSadarkaa 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Namoota walitti qabaa jiraSadarkaa 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Namoota walitti qabaa jiraSadarkaa 2Hojjettoota fayyaa simatamoo
- Fred Hutch/University of Washington Cancer Consortium, Seattle
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Namoota walitti qabaa jiraSadarkaa 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Namoota walitti qabaa jiraSadarkaa 1/2Hojjettoota fayyaa simatamoo
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Namoota walitti qabaa jiraSadarkaa 2/3
- Seattle Cancer Care Alliance, Seattle
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Namoota walitti qabaa jiraSadarkaa 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Namoota walitti qabaa jiraSadarkaa 1/2
- Fred Hutchinson Cancer Center, Seattle
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Namoota walitti qabaa jiraSadarkaa 2
- Fred Hutchinson Cancer Center, Seattle
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Namoota walitti qabaa jiraSadarkaa 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
Namoota walitti qabaa jiraSadarkaa 1
- Seattle Children's Hospital, Seattle
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Namoota walitti qabaa jiraSadarkaa 2
- Fred Hutchinson Cancer Research Center, Seattle
Novel Digital Application for Patients With Acute Leukemia
Namoota walitti qabaa jira
- Fred Hutchinson Cancer Research Center (FHCRC), Seattle
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Namoota walitti qabaa jiraSadarkaa 1
- Fred Hutchinson Cancer Center, Seattle
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- Fred Hutchinson Cancer Center, Seattle
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- Fred Hutchinson Cancer Center, Seattle
Qorannoo Leukemia Myeloidii Hamaa magaalota biroo keessatti
- Houston, TXQorannoo 85
- New York City, NYQorannoo 51
- Boston, MAQorannoo 44
- Baldwin Park, CAQorannoo 40
- Columbus, OHQorannoo 35
- Philadelphia, PAQorannoo 34
- Durham, NCQorannoo 33
- Atlanta, GAQorannoo 31
- Tampa, FLQorannoo 29
- Chicago, ILQorannoo 26
- Portland, ORQorannoo 25
- Washington, DCQorannoo 24
Qorannoo biroo Seattle keessatti
- Kansara Qara'a Non-Small CellQorannoo 53
- Saree (Gosoota Hunda)Qorannoo 49
- Kansarii ProstateQorannoo 42
- Saree OljooQorannoo 39
- Kansara MetastatikiiQorannoo 39
- Kansarii ColorectalQorannoo 34
- Dhibee QaraQorannoo 33
- Kansarii OvariiQorannoo 30
- Myeloma Baay’eeQorannoo 22
- Dukkana BladderQorannoo 21
- Myelodysplastic SyndromesQorannoo 21
- Leukemia Lymphoblasticii HamaaQorannoo 21
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.